Advertisement

What’s new in the Global Initiative for Asthma 2018 report and beyond

  • Kheng Yong Ong
review
  • 25 Downloads

Abstract

Background

The Global Initiative for Asthma (GINA) has regularly published and annually updated a global strategy for asthma management and prevention that has formed the basis for many national guidelines. The 2018 update of the GINA report incorporates new evidence following the routine twice-yearly cumulative review of the literature by the GINA Scientific Committee.

Methods

Recommendations in the 2018 edition were examined for new content and updates, and the scientific evidence behind these recommendations was examined and discussed. Focus was given to the management of asthma in adults in the general population and children more than 5 years of age. Selected new studies related to the management of asthma that may affect future recommendations were also discussed.

Results and discussion

There have been updates in the assessment of asthma, the role of fractional exhaled nitric oxide, and the stepwise treatment of asthma. Key messages from previous versions of the guidelines were also reiterated and updated with new evidence supporting previous recommendations. Changes and new recommendations may be expected in future editions based on new scientific evidence which has emerged in the recent months.

Keywords

Asthma Asthma guideline Asthma management and prevention Global Initiative for Asthma 

Abbreviations

ACO

Asthma-chronic obstructive pulmonary disease (COPD) overlap

AMAZES

Asthma and Macrolides: The Azithromycin Efficacy and Safety study

ATS

American Thoracic Society

CI

Confidence interval

COPD

Chronic obstructive pulmonary disease

ERS

European Respiratory Society

FDA

Food and Drug Administration

FENO

Fractional exhaled nitric oxide

FEV1

Forced expiratory volume in 1 s

FVC

Forced vital capacity

GINA

Global Initiative for Asthma

HR

Hazard ratio

ICS

Inhaled corticosteroid

IL-5

Interleukin 5

LABA

Long-acting beta agonists

LAMA

Long-acting muscarinic antagonist

LTRA

Leukotriene receptor antagonists

NAEPP

National Asthma Education and Prevention Program

NNT

Number needed to treat

OCS

Oral corticosteroids

OR

Odds ratio

PEF

Peak expiratory flow

RCT

Randomized controlled trial

SABA

Short-acting beta agonist

TENOR

The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens

Notes

Conflict of interest

K.Y. Ong declares that he has no competing interests.

References

  1. 1.
    Global Initiative for Asthma. Global strategy for asthma management and prevention. 2018. www.ginaasthma.org. Accessed 1 May 2018.Google Scholar
  2. 2.
    Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J. 2015;46:622–39.CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Haselkorn T, Fish JE, Zeiger RS, Szefler SJ, Miller DP, Chipps BE, et al. Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol 2009;124:895–902.e1-4CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Ulrik CS, Frederiksen J. Mortality and markers of risk of asthma death among 1,075 outpatients with asthma. Chest. 1995;108:10–5.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    den Dekker HT, Sonnenschein-van der Voort AMM, de Jongste JC, Anessi-Maesano I, Arshad SH, Barros H, et al. Early growth characteristics and the risk of reduced lung function and asthma: a meta-analysis of 25,000 children. J Allergy Clin Immunol. 2016;137:1026–35.CrossRefGoogle Scholar
  6. 6.
    Fahy JV. Type 2 inflammation in asthma—present in most, absent in many. Nat Rev Immunol. 2015;15:57–65.CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602–15.CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Pijnenburg MW, Hofhuis W, Hop WC, De Jongste JC. Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax. 2005;60:215–8.CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Petsky HL, Kew KM, Chang AB. Exhaled nitric oxide levels to guide treatment for children with asthma. Cochrane Database Syst Rev. 2016;  https://doi.org/10.1002/14651858.CD011439.pub2.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Petsky HL, Kew KM, Turner C, Chang AB. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database Syst Rev. 2016;  https://doi.org/10.1002/14651858.CD011440.pub2.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343:332–6.CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax. 2002;57:880–4.CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361:1071–6.CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013;  https://doi.org/10.1002/14651858.CD007313.pub3.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kew KM, Karner C, Mindus SM, Ferrara G. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013;  https://doi.org/10.1002/14651858.CD009019.pub2.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev. 2010;  https://doi.org/10.1002/14651858.CD005535.pub2.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Peters SP, Bleecker ER, Canonica GW, Park YB, Ramirez R, Hollis S, et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. N Engl J Med. 2016;375:850–60.CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Stempel DA, Raphiou IH, Kral KM, Yeakey AM, Emmett AH, Prazma CM, et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. N Engl J Med. 2016;374:1822–30.CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Rodrigo GJ, Castro-Rodriguez JA. What is the role of tiotropium in asthma?: a systematic review with meta-analysis. Chest. 2015;147:388–96.CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016;  https://doi.org/10.1002/14651858.CD011721.pub2.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Menzella F, Lusuardi M, Galeone C, Facciolongo N, Zucchi L. The clinical profile of benralizumab in the management of severe eosinophilic asthma. Ther Adv Respir Dis. 2016;10:534–48.CrossRefPubMedCentralGoogle Scholar
  22. 22.
    Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448–58.CrossRefPubMedCentralGoogle Scholar
  23. 23.
    Richards RN. Side effects of short-term oral corticosteroids. J Cutan Med Surg. 2008;12:77–81.CrossRefPubMedCentralGoogle Scholar
  24. 24.
    Kirkland SW, Vandenberghe C, Voaklander B, Nikel T, Campbell S, Rowe BH. Combined inhaled beta-agonist and anticholinergic agents for emergency management in adults with asthma. Cochrane Database Syst Rev. 2017;  https://doi.org/10.1002/14651858.CD001284.pub2.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax. 2004;59:94–9.CrossRefPubMedCentralGoogle Scholar
  26. 26.
    Quon BS, Fitzgerald JM, Lemiere C, Shahidi N, Ducharme FM. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev. 2010;  https://doi.org/10.1002/14651858.CD007524.pub2.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Kew KM, Quinn M, Quon BS, Ducharme FM. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev. 2016;  https://doi.org/10.1002/14651858.CD007524.pub4.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Oborne J, Mortimer K, Hubbard RB, Tattersfield AE, Harrison TW. Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Am J Respir Crit Care Med. 2009;180:598–602.CrossRefPubMedCentralGoogle Scholar
  29. 29.
    Reddel HK, Barnes DJ. Pharmacological strategies for self-management of asthma exacerbations. Eur Respir J. 2006;28:182–99.CrossRefPubMedCentralGoogle Scholar
  30. 30.
    McKeever T, Mortimer K, Wilson A, Walker S, Brightling C, Skeggs A, et al. Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations. N Engl J Med. 2018;378:902–10.CrossRefPubMedCentralGoogle Scholar
  31. 31.
    Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr., Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689–98.CrossRefPubMedCentralGoogle Scholar
  32. 32.
    Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:660–7.CrossRefPubMedCentralGoogle Scholar
  33. 33.
    National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007;120:S94–S138.CrossRefGoogle Scholar
  34. 34.
    Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–73.CrossRefPubMedCentralGoogle Scholar
  35. 35.
    Kew KM, Undela K, Kotortsi I, Ferrara G. Macrolides for chronic asthma. Cochrane Database Syst Rev. 2015;  https://doi.org/10.1002/14651858.CD002997.pub4.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Tong X, Guo T, Liu S, Peng S, Yan Z, Yang X, et al. Macrolide antibiotics for treatment of asthma in adults: a meta-analysis of 18 randomized controlled clinical studies. Pulm Pharmacol Ther. 2015;31:99–108.CrossRefPubMedCentralGoogle Scholar
  37. 37.
    Reiter J, Demirel N, Mendy A, Gasana J, Vieira ER, Colin AA, et al. Macrolides for the long-term management of asthma—a meta-analysis of randomized clinical trials. Allergy. 2013;68:1040–9.CrossRefPubMedCentralGoogle Scholar
  38. 38.
    Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:659–68.CrossRefPubMedCentralGoogle Scholar
  39. 39.
    Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378:2486–96.CrossRefPubMedCentralGoogle Scholar
  40. 40.
    Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475–85.CrossRefPubMedCentralGoogle Scholar
  41. 41.
    O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378:1865–76.CrossRefPubMedCentralGoogle Scholar
  42. 42.
    Bateman ED, Reddel HK, O’Byrne PM, Barnes PJ, Zhong N, Keen C, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378:1877–87.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, a part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PharmacySingapore General HospitalSingaporeSingapore
  2. 2.Allergy CentreSingapore General HospitalSingaporeSingapore

Personalised recommendations